Italia markets close in 8 hours 2 minutes
FTSE MIB
35.036,03 -362,79 (-1,02%) Dow Jones
40.003,59 +134,19 (+0,34%) Nasdaq
16.685,97 -12,33 (-0,07%) Nikkei 225
39.069,68 +282,30 (+0,73%) Petrolio
80,22 +0,16 (+0,20%) Bitcoin EUR
61.332,84 -507,51 (-0,82%)
NBIX Dec 2024 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:31AM EDT. Mercato aperto.
| Chiusura precedente | 17,40 |
| Aperto | 17,40 |
| Denaro | 0,00 |
| Lettera | 0,00 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 17,40 - 17,40 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.